{"id":"sorafenib-pazopanib","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Hypertension"},{"rate":"20-40%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Hand-foot skin reaction"},{"rate":"10-30%","effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Sorafenib and Pazopanib inhibit multiple kinases, including RAF, VEGFR, and PDGFR, which are involved in tumor growth, angiogenesis, and metastasis. This leads to a decrease in tumor size and a reduction in the formation of new blood vessels that supply the tumor.","oneSentence":"Sorafenib and Pazopanib are multi-kinase inhibitors that target various pathways involved in tumor growth and angiogenesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:35:27.248Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced renal cell carcinoma"},{"name":"Hepatocellular carcinoma"}]},"trialDetails":[{"nctId":"NCT02184416","phase":"","title":"Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-10-31","conditions":"Metastatic Renal Cell Carcinoma (mRCC)","enrollment":554},{"nctId":"NCT02029001","phase":"PHASE2","title":"Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment","status":"RECRUITING","sponsor":"Centre Leon Berard","startDate":"2014-03","conditions":"Malignant Solid Neoplasms","enrollment":900},{"nctId":"NCT04659343","phase":"","title":"TDM for Optimized Outcome in Patients With mRCC.","status":"RECRUITING","sponsor":"Niels Fristrup","startDate":"2020-11-01","conditions":"Kidney Cancer, Renal Cell Carcinoma Metastatic, Drug Toxicity","enrollment":200},{"nctId":"NCT05363072","phase":"","title":"A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-05-02","conditions":"Renal Cell Cancer, Renal Cell Carcinoma, Cancer of Kidney","enrollment":1112},{"nctId":"NCT02776644","phase":"","title":"Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-10-15","conditions":"Renal Cell Carcinoma","enrollment":1349},{"nctId":"NCT02551718","phase":"NA","title":"High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-09-11","conditions":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia","enrollment":34},{"nctId":"NCT01664182","phase":"PHASE2","title":"Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-08-01","conditions":"Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7","enrollment":41},{"nctId":"NCT01636908","phase":"NA","title":"Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2011-08","conditions":"Cancer, Advanced Solid Tumors","enrollment":43},{"nctId":"NCT02071719","phase":"","title":"Prediction of Response to Kinase Inhibitors Based on Protein Phosphorylation Profiles in Tumor Tissue From Advanced Renal Cell Cancer Patients","status":"TERMINATED","sponsor":"M. Labots","startDate":"2012-04","conditions":"Renal Cell Cancer","enrollment":6},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT02187302","phase":"PHASE2","title":"CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)","status":"COMPLETED","sponsor":"NewLink Genetics Corporation","startDate":"2014-07","conditions":"Metastatic Renal Cell Carcinoma","enrollment":115},{"nctId":"NCT00610012","phase":"","title":"Tumor Registry of Advanced Renal Cell Carcinoma","status":"COMPLETED","sponsor":"iOMEDICO AG","startDate":"2007-12","conditions":"Renal Cell Carcinoma","enrollment":1500},{"nctId":"NCT02638428","phase":"PHASE2","title":"Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2015-12","conditions":"Relapsed Pediatric Solid Tumor, Refractory Pediatric Solid Tumor, Relapsed Pediatric AML","enrollment":90},{"nctId":"NCT02406521","phase":"PHASE1","title":"Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2015-04","conditions":"Metastatic Renal Cell Carcinoma","enrollment":30},{"nctId":"NCT01731158","phase":"PHASE2","title":"Sequential Therapy in Metastatic Renal Cell Carinoma","status":"COMPLETED","sponsor":"Central European Society for Anticancer Drug Research","startDate":"2012-10","conditions":"Metastatic Renal Cell Carcinoma","enrollment":22},{"nctId":"NCT02560012","phase":"PHASE2","title":"Personalized Targeted Inhibitors Treatment in Renal Cell Cancer","status":"TERMINATED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2016-01-04","conditions":"Carcinoma, Renal Cell","enrollment":4},{"nctId":"NCT02086734","phase":"","title":"Perfusion CT as a Predictor for Response to Antiangiogenic Therapy in Patients With Metastasized Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2012-04","conditions":"Metastatic Renal Cancer","enrollment":60},{"nctId":"NCT02122003","phase":"PHASE2","title":"Second Line Sorafenib After Pazopanib in Patients With RCC","status":"TERMINATED","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2016-09","conditions":"Metastatic Renal Cell Carcinoma","enrollment":16},{"nctId":"NCT01613846","phase":"PHASE3","title":"Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II)","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2012-05","conditions":"Renal Cell Carcinoma","enrollment":544},{"nctId":"NCT01758575","phase":"","title":"Clinical Evaluation of the Underlying Mechanisms of Targeted Therapy Related Toxicities","status":"TERMINATED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2012-11","conditions":"Advanced or Metastatic Solid Malignancy","enrollment":8},{"nctId":"NCT01446224","phase":"","title":"Cardiovascular and Torsades de Pointes Monitoring for Pazopanib","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-12","conditions":"Carcinoma, Renal Cell","enrollment":1},{"nctId":"NCT01449825","phase":"","title":"Hepatic Monitoring for Pazopanib","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-12","conditions":"Carcinoma, Renal Cell","enrollment":1},{"nctId":"NCT01381614","phase":"","title":"Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (IHCIS)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03","conditions":"Carcinoma, Renal Cell","enrollment":1},{"nctId":"NCT01381601","phase":"","title":"Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03","conditions":"Carcinoma, Renal Cell","enrollment":1},{"nctId":"NCT01700699","phase":"","title":"Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors","status":"UNKNOWN","sponsor":"University of Salerno","startDate":"2012-10","conditions":"Differentiated Thyroid Cancer","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Sorafenib+Pazopanib","genericName":"Sorafenib+Pazopanib","companyName":"Technical University of Munich","companyId":"technical-university-of-munich","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sorafenib and Pazopanib are multi-kinase inhibitors that target various pathways involved in tumor growth and angiogenesis. Used for Advanced renal cell carcinoma, Hepatocellular carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}